ADC Therapeutics' ZYNLONTA Achieves 94% Response Rate in Lymphoma Trial

Lausanne, Wednesday, 11 December 2024.
The LOTIS-7 trial shows ZYNLONTA’s combination with glofitamab achieves a 94% overall response rate in relapsed or refractory diffuse large B-cell lymphoma, presenting promising treatment potential.